IMR Press / EJGO / Volume 43 / Issue 2 / DOI: 10.31083/j.ejgo4302040
Open Access Review
Treatment Progress in Triple Negative Breast Cancer
Show Less
1 Department of Obstetrics and Gynecology, Helios Hospital, 47805 Krefeld, Germany
2 Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
*Correspondence: michael.friedrich@helios-gesundheit.de (Michael Friedrich)
Academic Editor: Enrique Hernandez
Eur. J. Gynaecol. Oncol. 2022, 43(2), 341–352; https://doi.org/10.31083/j.ejgo4302040
Submitted: 22 November 2021 | Revised: 17 February 2022 | Accepted: 18 February 2022 | Published: 15 April 2022
(This article belongs to the Special Issue Breast Cancer)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 (BRCA1)-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.

Keywords
breast cancer
triple negative
chemotherapy
immunoncology
PD-L1
Parp
pembrolizumab
atezolizumab
olaparib
talozoparib
sacituzumab-govitecan
Share
Back to top